Dermatomyositis: Current and future treatments

Expert Review of Dermatology

Volumn 4, Issue 6, 2009, Pages 581-594

  Vleugels, Ruth Ann ^a   Callen, Jeffrey P ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b University of Louisville School of Medicine   (United States)

Author keywords

Amyopathic dermatomyositis; Dermatomyositis; Idiopathic inflammatory myopathies

Indexed keywords

ANTIHISTAMINIC AGENT; ANTIPRURITIC AGENT; AZATHIOPRINE; CALCINEURIN INHIBITOR; CAMPHOR; CHLORAMBUCIL; CHLOROQUINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DAPSONE; EFALIZUMAB; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; INFLIXIMAB; LEFLUNOMIDE; LIDOCAINE; MEPACRINE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PRAMOCAINE; PREDNISONE; RAPAMYCIN; RITUXIMAB; TACROLIMUS; TAMOXIFEN; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNINDEXED DRUG;

ABSENCE OF SIDE EFFECTS; ADJUVANT THERAPY; B CELL LYMPHOMA; CALCINOSIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DERMATOMYOSITIS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG PULSE THERAPY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHEMA; EXERCISE; FACE INJURY; HUMAN; HYPERTRIGLYCERIDEMIA; LEUKAPHERESIS; LIVER FIBROSIS; LUPUS ERYTHEMATOSUS; MONOTHERAPY; MYOSITIS; PATIENT CARE; PHOTOTHERAPY; PLASMAPHERESIS; PRIMARY HEALTH CARE; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SKIN DISEASE; STEM CELL TRANSPLANTATION; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION; UROGENITAL TRACT DISEASE; WHOLE BODY RADIATION;

EID: 73949109328     PISSN: 17469872     EISSN: None     Source Type: Journal    
DOI: 10.1586/edm.09.52     Document Type: Review

References (152)

1. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N. Engl. J. M Ed. 292 (7), 344-347 (1975).
2. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N. Engl. J. M Ed. 292 (8), 403-407 (1975).
3. Callen JP. Dermatomyositis. Lancet 355 (9197), 53-57 (2000).
4. Vleugels RA, Callen JP. Dermatomyositis. In: Dermatological Signs of Internal Disease. Callen JP, Jorizzo JL, Bolognia JL, Piette W, Zone JJ (Eds). Saunders/Elsevier, PA, USA (2009).
5. Hundley JL, Carroll CL, Lang W et al. Cutaneous symptoms of dermatomyositis significantly impact patients' quality of life J. Am. Acad. Dermatol. 54 (2), 217-220 (2006).
6. Sontheimer RD. Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sine myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J. Am. Acad. Dermatol. 46 (4), 626-636 (2002).
7. Gerami P, Schope JM, Mcdonald L, Walling HW, Sontheimer RD. A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis sine myositis) : a missing link within the spectrum of the idiopathic inflammatory myopathies. J. Am. Acad. Dermatol. 54 (4), 597-613 (2006).
8. Jorizzo JL. Dermatomyositis: practical aspects. Arch. Dermatol. 138 (1), 114-116 (2002).
9. Klein RQ, Teal V, Taylor L, Troxel AB, Werth VP. Number, characteristics, and classification of patients with dermatomyositis seen by dermatology and rheumatology departments at a large tertiary medical center. J. Am. Acad. Dermatol. 57 (6), 937-943 (2007).
10. Sontheimer RD. The management of dermatomyositis: current treatment options. Expert Opin. Pharmaco Ther. 5 (5), 1083-1099 (2004).
11. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet 362 (9388), 971-982 (2003).
12. Quain RD, Werth VP. Management of cutaneous dermatomyositis: current therapeutic options. Am. J. Clin. Dermatol. 7 (6), 341-351 (2006).
13. Choy EH, Hoogendijk JE, Lecky B, Winer JB. Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis. Cochrane Database Syst. Rev. 3, CD003643 (2005).
14. Iorizzo LJ 3rd, Jorizzo JL. The treatment and prognosis of dermatomyositis: an updated review. J. Am. Acad. Dermatol. 59 (1), 99-112 (2008).
15. Callen JP, Wortmann RL. Dermatomyositis. Clin. Dermatol. 24 (5), 363-373 (2006).
16. Sontheimer RD. Photoimmunology of lupus erythematosus and dermatomyositis: a speculative review. Photochem. Photo Biol.63 (5), 583-594 (1996).
17. Dourmishev L, Meffert H, Piazena H. Dermatomyositis: comparative studies of cutaneous photosensitivity in lupus erythematosus and normal subjects. Photodermatol. Photoimmunol. Photom Ed. 20 (5), 230-234 (2004).
18. Cheong WK, Hughes GR, Norris PG, Hawk JL. Cutaneous photosensitivity in dermatomyositis. Br. J. Dermatol. 131 (2), 205-208 (1994).
19. Callen JP. Photosensitivity in collagen vascular diseases. Semin. Cutan. Med. Surg. 18 (4), 293-296 (1999).
20. Yoshimasu T, Ohtani T, Sakamoto T, Oshima A, Furukawa F. Topical fk506 (tacrolimus) therapy for facial erythematous lesions of cutaneous lupus erythematosus and dermatomyositis. Eur. J. Dermatol. 12 (1), 50-52 (2002).
21. Ueda M, Makinodan R, Matsumura M, Ichihashi M. Successful treatment of amyopathic dermatomyositis with topical tacrolimus. Br. J. Dermatol. 148 (3), 595-596 (2003).
22. Hollar CB, Jorizzo JL. Topical tacrolimus 0.1% ointment for refractory skin disease in dermatomyositis: a pilot study. J. Dermatolog. Treat. 15 (1), 35-39 (2004).
23. Garcia-Doval I, Cruces M. Topical tacrolimus in cutaneous lesions of dermatomyositis: lack of effect in side-by-side comparison in five patients. Dermatology 209 (3), 247-248 (2004).
24. Wallace DJ. The use of chloroquine and hydroxychloroquine for non-infectious conditions other than rheumatoid arthritis or lupus: a critical review. Lupus 5 (Suppl. 1), S59-S64 (1996).
25. Woo TY, Callen JP, Voorhees JJ, Bickers DR, Hanno R, Hawkins C. Cutaneous lesions of dermatomyositis are improved by hydroxychloroquine. J. Am. Acad. Dermatol. 10 (4), 592-600 (1984).
26. James WD, Dawson N, Rodman OG. The treatment of dermatomyositis with hydroxchloroquine. J. Rheumatol. 12 (6), 1214-1216 (1985).
27. Cosnes A, Amaudric F, Gherardi R et al. Dermatomyositis without muscle weakness. Long-term follow-up of 12 patients without systemic corticosteroids. Arch. Dermatol. 131 (12), 1381-1385 (1995).
28. Dawkins MA, Jorizzo JL, Walker FO, Albertson D, Sinal SH, Hinds A. Dermatomyositis: a dermatology-based case series. J. Am. Acad. Dermatol. 38 (3), 397-404 (1998).
29. Olson NY, Lindsley CB. Adjunctive use of hydroxychloroquine in childhood dermatomyositis. J. Rheumatol. 16 (12), 1545-1547 (1989).
30. Bloom BJ, Tucker LB, Klein-Gitelman M, Miller LC, Schaller JG. Worsening of the rash of juvenile dermatomyositis with hydroxychloroquine therapy. J. Rheumatol. 21 (11), 2171-2172 (1994).
31. Pelle MT, Callen JP. Adverse cutaneous reactions to hydroxychloroquine are more common in patients with dermatomyositis than in patients with cutaneous lupus erythematosus. Arch. Dermatol. 138 (9), 1231-1233 (2002).
32. Ang GC, Werth VP. Combination antimalarials in the treatment of cutaneous dermatomyositis: a retrospective study. Arch. Dermatol. 141 (7), 855-859 (2005).
33. Drake LA, Dinehart SM, Farmer ER et al. Guidelines of care for dermatomyositis. American academy of dermatology. J. Am. Acad. Dermatol. 34 (5 Pt 1), 824-829 (1996).
34. Metzger AL, Bohan A, Goldberg LS, Bluestone R, Pearson CM. Polymyositis and dermatomyositis: combined methotrexate and corticosteroid therapy. Ann. Intern. M Ed. 81 (2), 182-189 (1974).
35. Kasteler JS, Callen JP. Low-dose methotrexate administered weekly is an effective corticosteroid-sparing agent for the treatment of the cutaneous manifestations of dermatomyositis. J. Am. Acad. Dermatol. 36 (1), 67-71 (1997).
36. Al-Mayouf S, Al-Mazyed A, Bahabri S. Efficacy of early treatment of severe juvenile dermatomyositis with intravenous methylprednisolone and methotrexate. Clin. Rheumatol. 19 (2), 138-141 (2000).
37. Zieglschmid-Adams ME, Pandya AG, Cohen SB, Sontheimer RD. Treatment of dermatomyositis with methotrexate. J. Am. Acad. Dermatol. 32 (5 Pt 1), 754-757 (1995).
38. Bunch TW. Prednisone and azathioprine for polymyositis: long-term followup. Arthritis Rheum. 24 (1), 45-48 (1981).
39. Joffe MM, Love LA, Leff RL et al. Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. Am. J. M Ed. 94 (4), 379-387 (1993).
40. Majithia V, Harisdangkul V. Mycophenolate mofetil (cellcept) : an alternative therapy for autoimmune inflammatory myopathy. Rheumatology (Oxford) 44 (3), 386-389 (2005).
41. Tausche AK, Meurer M. Mycophenolate mofetil for dermatomyositis. Dermatology 202 (4), 341-343 (2001).
42. Gelber AC, Nousari HC, Wigley FM. Mycophenolate mofetil in the treatment of severe skin manifestations of dermatomyositis: a series of 4 cases. J. Rheumatol. 27 (6), 1542-1545 (2000).
43. Edge JC, Outland JD, Dempsey JR, Callen JP. Mycophenolate mofetil as an effective corticosteroid-sparing therapy for recalcitrant dermatomyositis. Arch. Dermatol. 142 (1), 65-69 (2006).
44. Lueck CJ, Trend P, Swash M. Cyclosporin in the management of polymyositis and dermatomyositis. J. Neurol. Neurosurg. Psychiatry 54 (11), 1007-1008 (1991).
45. Grau JM, Herrero C, Casademont J, Fernandez-Sola J, Urbano-Marquez A. Cyclosporine A as first choice therapy for dermatomyositis. J. Rheumatol. 21 (2), 381-382 (1994).
46. Qushmaq KA, Chalmers A, Esdaile JM. Cyclosporin A in the treatment of refractory adult polymyositis/dermatomyositis: population based experience in 6 patients and literature review. J. Rheumatol. 27 (12), 2855-2859 (2000).
47. Vencovsky J, Jarosova K, Machacek S et al. Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis. Scand J. Rheumatol. 29 (2), 95-102 (2000).
48. Reiff A, Rawlings DJ, Shaham B et al. Preliminary evidence for cyclosporin A as an alternative in the treatment of recalcitrant juvenile rheumatoid arthritis and juvenile dermatomyositis. J. Rheumatol. 24 (12), 2436-2443 (1997).
49. Heckmatt J, Hasson N, Saunders C et al. Cyclosporin in juvenile dermatomyositis. Lancet 1 (8646), 1063-1066 (1989).
50. Kim HJ, Hong YK, Yoo WH. Dermatomyositis, complicated with pneumomediastinum, successfully treated with cyclosporine A: a case report and review of literature. Rheumatol. Int. 29 (9), 1101-1104 (2009).
51. Ozawa Y, Kurosaka D, Yokoyama T, Tajima N. Therapeutic efficacy of cyclosporin A in four cases of amyopathic dermatomyositis with rapidly progressive interstitial pneumonia. Ryumachi 40 (5), 798-809 (2000).
52. Sugisaki K, Takeda I, Iwadate H, Kanno T, Nishimaki T, Kasukawa R. Prevention of progression of interstitial lung lesions by early combination therapy with corticosteroids and cyclosporine/cyclophosphamide in two patients with amyopathic dermatomyositis. Fukushima J. Med. Sci. 48 (2), 103-110 (2002).
53. Shimojima Y, Ishii W, Kato T et al. Intractable skin necrosis and interstitial pneumonia in amyopathic dermatomyositis, successfully treated with cyclosporin A. Intern. M Ed. 42 (12), 1253-1258 (2003).
54. Ochi S, Nanki T, Takada K et al. Favorable outcomes with tacrolimus in two patients with refractory interstitial lung disease associated with polymyositis/dermatomyositis. Clin. Exp. Rheumatol. 23 (5), 707-710 (2005).
55. Oddis CV, Sciurba FC, Elmagd KA, Starzl TE. Tacrolimus in refractory polymyositis with interstitial lung disease. Lancet 353 (9166), 1762-1763 (1999).
56. Wilkes MR, Sereika SM, Fertig N, Lucas MR, Oddis CV. Treatment of antisynthetase-associated interstitial lung disease with tacrolimus. Arthritis Rheum. 52 (8), 2439-2446 (2005).
57. Mitsui T, Kuroda Y, Kunishige M, Matsumoto T. Successful treatment with tacrolimus in a case of refractory dermatomyositis. Intern. Med 44 (11), 1197-1199 (2005).
58. Hassan J, Van Der Net JJ, Van Royen-Kerkhof A. Treatment of refractory juvenile dermatomyositis with tacrolimus. Clin. Rheumatol. 27 (11), 1469-1471 (2008).
59. Martin Nalda A, Modesto Caballero C, Arnal Guimeral C, Boronat Rom M, Barcelo Garcia P. Efficacy of tacrolimus (FK-506) in the treatment of recalcitrant juvenile dermatomyositis: study of 6 cases. Med. Clin. 127 (18), 697-701 (2006).
60. Yamada A, Ohshima Y, Omata N, Yasutomi M, Mayumi M. Steroid-sparing effect of tacrolimus in a patient with juvenile dermatomyositis presenting poor bioavailability of cyclosporine A. Eur. J. Pediatr. 163 (9), 561-562 (2004).
61. Mok CC, To CH, Szeto ML. Successful treatment of dermatomyositis-related rapidly progressive interstitial pneumonitis with sequential oral cyclophosphamide and azathioprine. Scand J. Rheumatol. 32 (3), 181-183 (2003).
62. Meyer O, Hayem G, Palazzo E, Crestani B, Debray MP, Ballard M. Interstitial lung disease due to polymyositis or dermatomyositis: effect of a 6-month course of i.v. pulse cyclophosphamide. Clin. Exp. Rheumatol. 23 (5), 724 (2005).
63. Takashi S, Okubo Y, Yamazaki Y, Koizumi T, Sekiguchi M. Amyopathic dermatomyositis with interstitial pneumonia: effective treatment with cyclophosphamide pulse therapy. Nihon Kokyuki Gakkai Zasshi 37 (8), 647-651 (1999).
64. Yamasaki Y, Yamada H, Yamasaki M et al. Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis. Rheumatology (Oxford) 46 (1), 124-130 (2007).
65. Tsujimura S, Saito K, Tanaka Y. Complete resolution of dermatomyositis with refractory cutaneous vasculitis by intravenous cyclophosphamide pulse therapy. Intern. M Ed. 47 (21), 1935-1940 (2008).
66. Sinoway PA, Callen JP. Chlorambucil. An effective corticosteroid-sparing agent for patients with recalcitrant dermatomyositis. Arthritis Rheum. 36 (3), 319-324 (1993).
67. Cagnoli M, Marchesoni A, Tosi S. Combined steroid, methotrexate and chlorambucil therapy for steroid-resistant dermatomyositis. Clin. Exp. Rheumatol. 9 (6), 658-659 (1991).
68. Wallace DJ, Metzger AL, White KK. Combination immunosuppressive treatment of steroid-resistant dermatomyositis/polymyositis. Arthritis Rheum. 28 (5), 590-592 (1985).
69. Konohana A, Kawashima J. Successful treatment of dermatomyositis with dapsone. Clin. Exp. Dermatol. 19 (4), 367 (1994).
70. Cohen JB. Cutaneous involvement of dermatomyositis can respond to dapsone therapy. Int. J. Dermatol. 41 (3), 182-184 (2002).
71. Stirling DI. Thalidomide and its impact in dermatology. Semin. Cutan. Med. Surg. 17 (4), 231-242 (1998).
72. Flores-Suarez LF, Morales H, Angeles A, Kraus A. Drug-induced amyopathic dermatomyositis. J. Clin. Rheumatol. 8 (1), 50-54 (2002).
73. Lange U, Piegsa M, Muller-Ladner U, Strunk J. Anti-JO-1 antibody positive polymyositis - successful therapy with leflunomide. Autoimmunity 39 (3), 261-264 (2006).
74. Sangle VS, Sangle SR, D'Cruz DP. Leflunomide as a remission-maintaining therapy in difficult-to-treat dermatomyositis. Ann. Rheum. Dis. 67 (5), 723 (2008).
75. Boswell JS, Costner MI. Leflunomide as adjuvant treatment of dermatomyositis. J. Am. Acad. Dermatol. 58 (3), 403-406 (2008).
76. Hengstman G, Van Den Hoogen F, Van Engelen B, Barrera P, Netea M, Van De Putte Nijmegen L. Anti-TNF blockage with infliximab (remicade) in polymyositis and dermatomyositis. Arthritis Rheum. 43 (Suppl.), S193 (2000).
77. Norman R, Greenberg RG, Jackson JM. Case reports of etanercept in inflammatory dermatoses. J. Am. Acad. Dermatol. 54 (3 Suppl. 2), S139-S142 (2006).
78. Selva-O'Callaghan A, Martinez-Costa X, Solans-Laque R, Mauri M, Capdevila JA, Vilardell-Tarres M. Refractory adult dermatomyositis with pneumatosis cystoides intestinalis treated with infliximab. Rheumatology (Oxford) 43 (9), 1196-1197 (2004).
79. Sprott H, Glatzel M, Michel BA. Treatment of myositis with etanercept (enbrel), a recombinant human soluble fusion protein of TNF-α type II receptor and IgG1. Rheumatology (Oxford) 43 (4), 524-526 (2004).
80. Korkmaz C, Temiz G, Cetinbas F, Buyukkidan B. Successful treatment of alveolar hypoventilation due to dermatomyositis with anti-tumour necrosis factor-α. Rheumatology (Oxford) 43 (7), 937-938 (2004).
81. Efthimiou P, Schwartzman S, Kagen LJ. Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients. Ann. Rheum. Dis. 65 (9), 1233-1236 (2006).
82. Riley P, McCann LJ, Maillard SM, Woo P, Murray KJ, Pilkington CA. Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis. Rheumatology (Oxford) 47 (6), 877-880 (2008).
83. Miller M, Mendez E, Klein-Gitelman M. Use of etanercept in juvenile dermatomyositis. Arthritis Rheum. 46 (Suppl.), S306 (2002).
84. Saddeh CK. Etanercept is effective in the treatment of polymyositis/dermatomyositis which is refractory to conventional therapy including steroids and other disease modifying agents. Arthritis Rheum. 43 (Suppl.), S193 (2000).
85. Nzeusseu A, Durez P, Houssiau H, Devogelaer J. Successful use of infliximab in a case of refractory juvenile dermatomyositis. Arthritis Rheum. 43 (Suppl.), S193 (2000).
86. Dastmalchi M, Grundtman C, Alexanderson H et al. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann. Rheum. Dis. 67 (12), 1670-1677 (2008).
87. Iannone F, Scioscia C, Falappone PC, Covelli M, Lapadula G. Use of etanercept in the treatment of dermatomyositis: a case series. J. Rheumatol. 33 (9), 1802-1804 (2006).
88. Flendrie M, Vissers WH, Creemers MC, De Jong EM, Van De Kerkhof PC, Van Riel PL. Dermatological conditions during TNF-α-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res. Ther. 7 (3), R666-R676 (2005).
89. Hall HA, Zimmermann B. Evolution of dermatomyositis during therapy with a tumor necrosis factor α inhibitor. Arthritis Rheum. 55 (6), 982-984 (2006).
90. Huber A, Gaffal E, Bieber T, Tuting T, Wenzel J. Treatment of recalcitrant dermatomyositis with efalizumab. Acta Derm Venereol. 86 (3), 254-255 (2006).
91. Noss EH, Hausner-Sypek DL, Weinblatt ME. Rituximab as therapy for refractory polymyositis and dermatomyositis. J. Rheumatol. 33 (5), 1021-1026 (2006).
92. Chiappetta N, Steier J, Gruber B. Rituximab in the treatment of refractory dermatomyositis. J. Clin. Rheumatol. 11 (5), 264-266 (2005).
93. Gottenberg JE, Guillevin L, Lambotte O et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann. Rheum. Dis. 64 (6), 913-920 (2005).
94. Lambotte O, Kotb R, Maigne G, Blanc FX, Goujard C, Delfraissy JF. Efficacy of rituximab in refractory polymyositis. J. Rheumatol. 32 (7), 1369-1370 (2005).
95. Kaposztas Z, Etheridge WB, Kahan BD. Case report: successful treatment of posttransplant lymphoproliferative disorder and quiescence of dermatomyositis with rituximab and sirolimus. Transplant. Proc. 40 (5), 1744-1746 (2008).
96. Touma Z, Arayssi T, Kibbi L, Masri AF. Successful treatment of cardiac involvement in dermatomyositis with rituximab. Joint Bone Spine 75 (3), 334-337 (2008).
97. Feist E, Dorner T, Sorensen H, Burmester GR. Longlasting remissions after treatment with rituximab for autoimmune myositis. J. Rheumatol. 35 (6), 1230-1232 (2008).
98. Dinh HV, McCormack C, Hall S, Prince HM. Rituximab for the treatment of the skin manifestations of dermatomyositis: a report of 3 cases. J. Am. Acad. Dermatol. 56 (1), 148-153 (2007).
99. Levine TD. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum. 52 (2), 601-607 (2005).
100. Sultan SM, Ng KP, Edwards JC, Isenberg DA, Cambridge G. Clinical outcome following β cell depletion therapy in eight patients with refractory idiopathic inflammatory myopathy. Clin. Exp. Rheumatol. 26 (5), 887-893 (2008).
101. Cooper MA, Willingham DL, Brown DE, French AR, Shih FF, White AJ. Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients. Arthritis Rheum. 56 (9), 3107-3111 (2007).
102. Lang BA, Laxer RM, Murphy G, Silverman ED, Roifman CM. Treatment of dermatomyositis with intravenous γ globulin. Am. J. M Ed. 91 (2), 169-172 (1991).
103. Cherin P, Herson S, Wechsler B et al. Efficacy of intravenous γglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients. Am. J. M Ed. 91 (2), 162-168 (1991).
104. Jann S, Beretta S, Moggio M, Adobbati L, Pellegrini G. High-dose intravenous human immunoglobulin in polymyositis resistant to treatment. J. Neurol. Neurosurg. Psychiatry 55 (1), 60-62 (1992).
105. Mastaglia FL, Phillips BA, Zilko PJ. Immunoglobulin therapy in inflammatory myopathies. J. Neurol. Neurosurg. Psychiatry 65 (1), 107-110 (1998).
106. Danieli MG, Malcangi G, Palmieri C et al. Cyclosporin A and intravenous immunoglobulin treatment in polymyositis/dermatomyositis. Ann. Rheum. Dis. 61 (1), 37-41 (2002).
107. Danieli MG, Calcabrini L, Calabrese V, Marchetti A, Logullo F, Gabrielli A. Intravenous immunoglobulin as add on treatment with mycophenolate mofetil in severe myositis. Autoimmun. Rev. 9 (2), 124-127 (2009).
108. Suzuki Y, Hayakawa H, Miwa S et al. Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis/dermatomyositis. Lung 187 (3), 201-206 (2009).
109. Al-Mayouf SM, Laxer RM, Schneider R, Silverman ED, Feldman BM. Intravenous immunoglobulin therapy for juvenile dermatomyositis: efficacy and safety. J. Rheumatol. 27 (10), 2498-2503 (2000).
110. Sansome A, Dubowitz V. Intravenous immunoglobulin in juvenile dermatomyositis - four year review of nine cases. Arch. Dis. Child. 72 (1), 25-28 (1995).
111. Peake MF, Perkins P, Elston DM, Older SA, Vinson R P. Cutaneous ulcers of refractory adult dermatomyositis responsive to intravenous immunoglobulin. Cutis 62 (2), 89-93 (1998).
112. Sadayama T, Miyagawa S, Shirai T. Low-dose intravenous immunoglobulin therapy for intractable dermatomyositis skin lesions. J. Dermatol. 26 (7), 457-459 (1999).
113. Dalakas MC, Illa I, Dambrosia JM et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N. Engl. J. M Ed. 329 (27), 1993-2000 (1993).
114. Dalakas MC. The role of high-dose immune globulin intravenous in the treatment of dermatomyositis. Int. Immunopharmacol. 6 (4), 550-556 (2006).
115. Barbasso Helmers S, Dastmalchi M, Alexanderson H et al. Limited effects of high-dose intravenous immunoglobulin (IVIg) treatment on molecular expression in muscle tissue of patients with inflammatory myopathies. Ann. Rheum. Dis. 66 (10), 1276-1283 (2007).
116. Miller FW, Leitman SF, Cronin ME et al. Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis. N. Engl. J. M Ed. 326 (21), 1380-1384 (1992).
117. Sereda D, Werth VP. Improvement in dermatomyositis rash associated with the use of antiestrogen medication. Arch. Dermatol. 142 (1), 70-72 (2006).
118. Kelly JJ, Madoc-Jones H, Adelman LS, Andres PL, Munsat TL. Response to total body irradiation in dermatomyositis. Muscle Nerve 11 (2), 120-123 (1988).
119. Nadiminti U, Arbiser JL. Rapamycin (sirolimus) as a steroid-sparing agent in dermatomyositis. J. Am. Acad. Dermatol. 52 (2 Suppl. 1), 17-19 (2005).
120. Saccardi R, Di Gioia M, Bosi A. Haematopoietic stem cell transplantation for autoimmune disorders. Curr. Opin. Hematol. 15 (6), 594-600 (2008).
121. Van Laar JM, Tyndall A. Adult stem cells in the treatment of autoimmune diseases. Rheumatology (Oxford) 45 (10), 1187-1193 (2006).
122. Tyndall A, Passweg J, Gratwohl A. Haemopoietic stem cell transplantation in the treatment of severe autoimmune diseases 2000. Ann. Rheum. Dis. 60 (7), 702-707 (2001).
123. Tsukamoto H, Nagafuji K, Horiuchi T et al. A Phase I-II trial of autologous peripheral blood stem cell transplantation in the treatment of refractory autoimmune disease. Ann. Rheum. Dis. 65 (4), 508-514 (2006).
124. Wu FQ, Luan Z, Lai JM et al. Treatment of refractory rheumatism among preschool children with autologous peripheral blood hematopoietic stem cell transplantation]. Zhonghua Er Ke Za Zhi 45 (11), 809-813 (2007).
125. Oryoji K, Himeji D, Nagafuji K et al. Successful treatment of rapidly progressive interstitial pneumonia with autologous peripheral blood stem cell transplantation in a patient with dermatomyositis. Clin. Rheumatol. 24 (6), 637-640 (2005).
126. Matsuoka Y, Miyajima S, Okada N. A case of calcinosis universalis successfully treated with low-dose warfarin. J. Dermatol. 25 (11), 716-720 (1998).
127. Harel L, Harel G, Korenreich L, Straussberg R, Amir J. Treatment of calcinosis in juvenile dermatomyositis with probenecid: the role of phosphorus metabolism in the development of calcifications. J. Rheumatol. 28 (5), 1129-1132 (2001).
128. Vinen CS, Patel S, Bruckner FE. Regression of calcinosis associated with adult dermatomyositis following diltiazem therapy. Rheumatology (Oxford) 39 (3), 333-334 (2000).
129. Abdallah-Lotf M, Grasland A, Vinceneux P, Sigal-Grinberg M. Regression of cutis calcinosis with diltiazem in adult dermatomyositis. Eur. J. Dermatol. 15 (2), 102-104 (2005).
130. Wang WJ, Lo WL, Wong CK. Calcinosis cutis in juvenile dermatomyositis: remarkable response to aluminum hydroxide therapy. Arch. Dermatol. 124 (11), 1721-1722 (1988).
131. Mukamel M, Horev G, Mimouni M. New insight into calcinosis of juvenile dermatomyositis: a study of composition and treatment. J. Pediatr. 138 (5), 763-766 (2001).
132. Ambler GR, Chaitow J, Rogers M, Mcdonald DW, Ouvrier RA. Rapid improvement of calcinosis in juvenile dermatomyositis with alendronate therapy. J. Rheumatol. 32 (9), 1837-1839 (2005).
133. Downey EC Jr, Woolley MM, Hanson V. Required surgical therapy in the pediatric patient with dermatomyositis. Arch Surg 123 (9), 1117-1120 (1988).
134. Wu JJ, Metz BJ. Calcinosis cutis of juvenile dermatomyositis treated with incision and drainage. Dermatol. Surg. 34 (4), 575-577 (2008).
135. Pachman LM. Juvenile dermatomyositis: decreased calcinosis with intermittent high-dose intravenous methylprednisolone therapy. Arthritis Rheum. 37 (Suppl.), 429 (1994).
136. Oliveri MB, Palermo R, Mautalen C, Hubscher O. Regression of calcinosis during diltiazem treatment in juvenile dermatomyositis. J. Rheumatol. 23 (12), 2152-2155 (1996).
137. Kalajian AH, Perryman JH, Callen JP. Intravenous immunoglobulin therapy for dystrophic calcinosis cutis: unreliable in our hands. Arch. Dermatol. 145 (3), 334 (2009).
138. Rider LG, Miller FW. Classification and treatment of the juvenile idiopathic inflammatory myopathies. Rheum. Dis. Clin. North Am. 23 (3), 619-655 (1997).
139. Pachman LM. Juvenile dermatomyositis. Pathophysiology and disease expression. Pediatr. Clin. North Am. 42 (5), 1071-1098 (1995).
140. Fisler RE, Liang MG, Fuhlbrigge RC, Yalcindag A, Sundel RP. Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis. J. Am. Acad. Dermatol. 47 (4), 505-511 (2002).
141. Bowyer SL, Blane CE, Sullivan DB, Cassidy JT. Childhood dermatomyositis: factors predicting functional outcome and development of dystrophic calcification. J. Pediatr. 103 (6), 882-888 (1983).
142. Pachman LM, Hayford JR, Chung A et al. Juvenile dermatomyositis at diagnosis: clinical characteristics of 79 children. J. Rheumatol. 25 (6), 1198-1204 (1998).
143. Miller LC, Michael AF, Kim Y. Childhood dermatomyositis. Clinical course and long-term follow-up. Clin. Pediatr. (Phila.) 26 (11), 561-566 (1987).
144. Shehata R, Al-Mayouf S, Al-Dalaan A, Al-Mazaid A, Al-Balaa S, Bahabri S. Juvenile dermatomyositis: clinical profile and disease course in 25 patients. Clin. Exp. Rheumatol. 17 (1), 115-118 (1999).
145. Kim S, El-Hallak M, Dedeoglu F, Zurakowski D, Fuhlbrigge RC, Sundel R P. Complete and sustained remission of juvenile dermatomyositis resulting from aggressive treatment. Arthritis Rheum. 60 (6), 1825-1830 (2009).
146. Alexanderson H. Exercise effects in patients with adult idiopathic inflammatory myopathies. Curr. Opin. Rheumatol. 21 (2), 158-163 (2009).
147. Alexanderson H. Exercise: an important component of treatment in the idiopathic inflammatory myopathies. Curr. Rheumatol. Rep. 7 (2), 115-124 (2005).
148. Alexanderson H, Dastmalchi M, Esbjornsson-Liljedahl M, Opava CH, Lundberg IE. Benefits of intensive resistance training in patients with chronic polymyositis or dermatomyositis. Arthritis Rheum. 57 (5), 768-777 (2007).
149. Alexanderson H, Lundberg IE. The role of exercise in the rehabilitation of idiopathic inflammatory myopathies. Curr. Opin. Rheumatol. 17 (2), 164-171 (2005).
150. Alexanderson H, Stenstrom CH, Lundberg I. Safety of a home exercise programme in patients with polymyositis and dermatomyositis: a pilot study. Rheumatology (Oxford) 38 (7), 608-611 (1999).
151. De Salles Painelli V, Gualano B, Artioli GG et al. The possible role of physical exercise on the treatment of idiopathic inflammatory myopathies. Autoimmun. Rev. 8 (5), 355-359 (2009).
152. Wiesinger GF, Quittan M, Aringer M et al. Improvement of physical fitness and muscle strength in polymyositis/dermatomyositis patients by a training programme. Br. J. Rheumatol. 37 (2), 196-200 (1998). 153 Wiesinger GF, Quittan M, Graninger M et al. Benefit of 6 months long-term physical training in polymyositis/dermatomyositis patients. Br. J. Rheumatol. 37 (12), 1338-1342 (1998). 154 Maillard SM, Jones R, Owens CM et al. Quantitative assessments of the effects of a single exercise session on muscles in juvenile dermatomyositis. Arthritis Rheum. 53 (4), 558-564 (2005).